Alzamend Neuro, Inc. (ALZN) - 10-K Summary
Business Context and Reporting Period
Company: Alzamend Neuro, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended April 30, 2026
Business Overview: Alzamend is a clinical-stage biopharmaceutical company developing novel treatments for Alzheimer's disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). The company has no commercial revenue and relies on equity financing to fund operations.
Pipeline:
- AL001: An ionic cocrystal of lithium, salicylate, and proline. Currently in Phase II "Lithium in Brain" imaging trials. Recent data (March/April 2026) indicated superior brain penetration and faster uptake compared to standard lithium carbonate.
- ALZN002: A cell-based therapeutic vaccine for Alzheimer's. Phase I/IIA trial is currently on hold due to the termination of the contract research organization (CRO) in February 2024. Restart is not expected until Q1 2027.
Key Financial Metrics
| Metric | Fiscal Year 2026 | Fiscal Year 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,772,382) | $(4,514,853) |
| Operating Expenses | $8,766,841 | $4,496,824 |
| Cash and Cash Equivalents (End of Period) | $710,689 | $3,948,658 |
| Accumulated Deficit | $(67,307,643) | $(58,535,261) |
| Stockholders' Equity | $733,211 | $3,968,222 |
| Net Cash Used in Operating Activities | $(8,067,813) | $(6,568,186) |
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss increased by 94% (from $4.5M to $8.8M) and operating expenses rose by 95% (from $4.5M to $8.8M). This was driven primarily by a 157% increase in Research and Development (R&D) expenses ($3.6M vs $1.4M) due to Phase II clinical trial fees, and a 67% increase in General and Administrative (G&A) expenses ($5.1M vs $3.1M) due to higher legal fees related to litigation with a former CRO.
- Cash Position: Cash reserves decreased by approximately $3.2 million, dropping from $3.9 million to $0.7 million.
- Equity Dilution: The company raised approximately $4.8 million through financing activities in FY2026, including the sale of convertible preferred stock and an "at-the-market" (ATM) offering of common stock.
- Stockholder Equity: Stockholders' equity declined significantly to $0.7 million, falling below the Nasdaq minimum listing requirement of $2.5 million.
Guidance, Outlook, Risks, and Unusual Items
Going Concern: The independent auditor has issued a report expressing substantial doubt about the company's ability to continue as a going concern. Management states that current cash ($711,000) is insufficient to fund operations for the next 12 months. Additional capital is required to continue clinical trials.
Nasdaq Compliance: The company received notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement. A plan to regain compliance was submitted, with a deadline of September 16, 2026. Failure to comply could result in delisting.
Internal Controls: Management identified a material weakness in internal control over financial reporting due to insufficient resources in the accounting department, restricting the ability to perform sufficient reviews of journal entries and reconciliations.
Clinical Outlook:
- AL001: Phase II trials for BD are underway with topline data expected in Q4 2026. Trials for MDD and PTSD are expected to commence in Q4 2026, followed by Alzheimer's in Q1 2027.
- ALZN002: Development is delayed. The company is seeking a replacement CRO and does not expect to restart the trial until Q1 2027.
Risks: High dependence on successful clinical outcomes; potential loss of licensing rights if milestones are not met; reliance on third-party CROs; and the need for substantial additional funding.
Key Facts for Investor Verification
- Liquidity Runway: Verify the company's ability to raise capital immediately, as cash on hand ($711k) is insufficient for 12 months of operations.
- Nasdaq Delisting Risk: Monitor the company's progress in regaining compliance with Nasdaq listing rules by the September 16, 2026 deadline.
- ALZN002 CRO Status: Confirm the engagement of a new CRO to restart the delayed Phase I/IIA trial, which is critical for the second product candidate.
- Internal Control Remediation: Assess the timeline and effectiveness of remediation plans for the identified material weakness in financial reporting.
- Litigation Costs: Monitor the outcome and cost impact of the lawsuit against the former CRO (Biorasi), which contributed to the spike in legal fees.